Close Menu


The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.

The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.

The Singapore-based molecular diagnostics firm plans to use the funds for regulatory approvals and commercialization of its lead epigenetics-based test for breast cancer. 

The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.